ArticleThe Journal of biological chemistry2016
Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone.
Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 225 citations in OpenAlex.
- Genetic polymorphisms analysis of pharmacogenomic VIP variants in Bai ethnic group from China.Molecular genetics & genomic medicine · 2019Trial
- Anti-Inflammatory Activity of Monoterpene Phenol Dimers fromACS omega · 2026Article
- Molecular Docking of Natural Products: Critical Appraisal of Current Methodology and Practical Guidelines.Molecules (Basel, Switzerland) · 2026Review
- In vivo and In Silico Assessment of Acampe papillosa (Lindl.) Lindl. Seed Extract: A Multi-Pharmacological Approach.Cell biochemistry and biophysics · 2026Article
- Chemical Profiling and Redox-Target Mapping of Antioxidant Fractions fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Exploring the Anti-Inflammatory Potential ofPlants (Basel, Switzerland) · 2026Article
- An In Silico Study of Resveratrol Derivatives as Dual Inhibitors of Cyclooxygenase-2 (COX-2) and 5-Lipoxygenase (5-LOX) in Cancer Therapy.Biotechnology and applied biochemistry · 2026Article
- In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma.Chirality · 2026Article
- Integrated experimental and computational characterization of bioactive metabolites from Streptomyces paradoxus GH53 with antimicrobial, antioxidant, and antitumor activities.Scientific reports · 2026Article
- Machine Learning-Aided Drug Repurposing for Screening COX-2 Inhibitors from Traditional Chinese Medicines.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Molecular and Pharmacokinetic Rationale for the Use ofMolecules (Basel, Switzerland) · 2026Article
- Synthesis of 4-Hydroxyphenylamino-Naphthoquinones as Paracetamol-Inspired Analogs: Chemical, In Silico, and Phenotypic Pharmacological Evaluation.Pharmaceutics · 2026Article
- Synthesis, characterization, molecular docking and in vitro anti-arthritic activity of some novel spiro [1,3,4] thiadiazole derivatives based on thioxoacetamides.BMC chemistry · 2026Article
- Exploring the impact of the innovative compound 3-(3-(4-hydroxy-2-oxo-2H-chromen-3-yl)-5-(pyridin-3-yl)-1H-pyrazol-1-yl) indolin-2-one on accelerating wound recovery.Scientific reports · 2026Article
- AI-guided competitive docking for virtual screening and compound efficacy prediction.npj drug discovery · 2026Article
- Anti-Inflammatory Effects of Bisacurone Isolated fromMolecules (Basel, Switzerland) · 2026Article
- Integrative transcriptomic and structural analysis identifies PTGS2 as a key target in ischemic stroke associated with neuroinflammation.Molecular diversity · 2026Article
- Polyphenol-based therapeutics for glioblastoma: validation from In-vitro cell viability assay and integrated onco-omics computational analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Phthalimide Derivatives as Anti-Inflammatory Agents: In Silico COX-2 Targeting and In Vitro Inhibition of PGEPharmaceutics · 2026Article
- Potential Nutraceutical Properties ofMolecules (Basel, Switzerland) · 2026Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cyclooxygenase-2 (COX-2) catalyzes the oxygenation of arachidonic acid (AA) and endocannabinoid substrates, placing the enzyme at a unique junction between the eicosanoid and endocannabinoid signaling pathways. COX-2 is a sequence homodimer, but the enzyme displays half-of-site reactivity, such that only one monomer of the dimer is active at a given time. Certain rapid reversible, competitive nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit COX-2 in a substrate-selective manner, with the binding of inhibitor to a single monomer sufficient to inhibit the oxygenation of endocannabinoids but not arachidonic acid. The underlying mechanism responsible for substrate-selective inhibition has remained elusive. We utilized structural and biophysical methods to evaluate flufenamic acid, meclofenamic acid, mefenamic acid, and tolfenamic acid for their ability to act as substrate-selective inhibitors. Crystal structures of each drug in complex with human COX-2 revealed that the inhibitor binds within the cyclooxygenase channel in an inverted orientation, with the carboxylate group interacting with Tyr-385 and Ser-530 at the top of the channel. Tryptophan fluorescence quenching, continuous-wave electron spin resonance, and UV-visible spectroscopy demonstrate that flufenamic acid, mefenamic acid, and tolfenamic acid are substrate-selective inhibitors that bind rapidly to COX-2, quench tyrosyl radicals, and reduce higher oxidation states of the heme moiety. Substrate-selective inhibition was attenuated by the addition of the lipid peroxide 15-hydroperoxyeicosatertaenoic acid. Collectively, these studies implicate peroxide tone as an important mechanistic component of substrate-selective inhibition by flufenamic acid, mefenamic acid, and tolfenamic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.